Evalutation of mycophenolic acid systemic exposure by limited sampling strategy in kidney transplant recipients receiving enteric-coated mycophenolate sodium (EC-MPS) and cyclosporine

Nephrology Dialysis Transplantation

Volumn 26, Issue 9, 2011, Pages 3019-3025

  Capone, Domenico ^a   Tarantino, Giovanni ^a   Kadilli, Irket ^a   Polichetti, Giuliano ^a   Basile, Vincenzo ^a   Federico, Stefano ^a   Sabbatini, Massimo ^a  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

Author keywords

enteric coated mycophenolate sodium; immunossuppression; kidney transplanted recipients; limited sampling strategy; MPA AUC

Indexed keywords

CYCLOSPORIN; ENTERIC COATED MYCOPHENOLATE SODIUM; MYCOPHENOLIC ACID; UNCLASSIFIED DRUG;

ADULT; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EXPOSURE; FEMALE; GRAFT RECIPIENT; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; MALE; MULTIPLE REGRESSION; PRIORITY JOURNAL;

ANTIBIOTICS, ANTINEOPLASTIC; AREA UNDER CURVE; CYCLOSPORINE; DRUG MONITORING; FEMALE; FOLLOW-UP STUDIES; GRAFT REJECTION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY FAILURE, CHRONIC; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; MYCOPHENOLIC ACID; PRODRUGS; PROGNOSIS; SURVIVAL RATE; TABLETS, ENTERIC-COATED; TISSUE DISTRIBUTION;

EID: 80053187747     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfq819     Document Type: Article

References (30)

1. Hughes SE, Gruber SA. New immunosuppressive drugs in organ transplantation. J Clin Pharmacol 1996; 36: 1081-1092 (Pubitemid 27056934)
2. Bullingham RE, Nicholls AJ, Kamm BR. Clinical Pharmacokinetics of mycophenolate mofetil. Clin Pharmacokin 1998; 34: 429-455 (Pubitemid 28273453)
3. Staatz CE, Tett SE. Clinical pharmacokinetics and pharmacodynamics of mycophenolate in solid organ transplant recipients. Clin Pharmacokinet 2007; 46: 13-58 (Pubitemid 46091591)
4. Knight SR, Morris PJ. Does the evidence support the use of mycophenolate mofetil therapeutic drug monitoring in clinical practice? A systematic review. Transplantation 2008; 85: 1675-1685
5. Le Meur Y, Büchler M, Thierry A et al. Individualized mycophenolate mofetil dosing based on drug exposure significantly improves patient outcomes after renal transplantation. Am J Transplant 2007; 7: 2496-2503 (Pubitemid 47566324)
6. van Gelder T, Silva HT, de Fijter JWet al. Comparing mycophenolate mofetil regimens for de novo renal transplant recipients: the fixeddose concentration-controlled trial. Transplantation 2008; 86: 1043-1051
7. Kuypers DR, de Jonge H, Naesens M et al. Current target ranges of mycophenolic acid exposure and drug-related adverse events: a 5-year, open-label, prospective, clinical follow-up study in renal allograft recipients. Clin Ther 2008; 30: 673-683 (Pubitemid 351689045)
8. Cattaneo D, Cortinovis M, Baldelli S et al. Pharmacokinetics of mycophenolate sodium and comparison with the mofetil formulation in stable kidney transplant recipients. Clin J Am Soc Nephrol 2007; 2: 1147-1155
9. Ghio L, Ferraresso M, Zacchello G et al. Longitudinal evaluation of mycophenolic acid pharmacokinetics in pediatric kidney transplant recipients. The role of post-transplant clinical and therapeutic variables. Clin Transplant 2009; 23: 264-270
10. Sánchez-Fructuoso A, de la Higuera MA, Giorgi M et al. Inadequate mycophenolic acid exposure and acute rejection in kidney transplantation. Transplant Proc 2009; 41: 2104-2105
11. Weber LT, Shipkova M, Armstrong VW et al. Comparison of the Emit immunoassay with HPLC for therapeutic drug monitoring of mycophenolic acid in pediatric renal-transplant recipients on mycophenolate mofetil therapy. Clin Chem 2002; 48: 517-525 (Pubitemid 34174582)
12. Sánchez-Fructuoso A, Ruiz JC, Rengel M et al. Use of mycophenolate sodium in stable renal transplant recipients in Spain: preliminary results of the MIDATA study. Transplant Proc 2009; 41: 2309-2312
13. Doria C, Ramirez CB, Frank AM et al. Use of enteric-coated mycophenolate sodium in liver transplant patients with intestinal intolerance caused by mycophenolate mofetil. Clin Transplant 2009; 23: 882-886
14. Bunnapradist S, Ambühl PM. Impact of gastrointestinal-related side effects on mycophenolate mofetil dosing and potential therapeutic strategies. Clin Transplant 2008; 22: 815-821
15. Cooper M, Deering KL, Slakey DP et al. Comparing outcomes associated with dose manipulations of enteric-coated mycophenolate sodium versus mycophenolate mofetil in renal transplant recipients. Transplantation 2009; 88: 514-520
16. Sabbatini M, Capone D, Gallo R et al. EC-MPS permits lower gastrointestinal symptom burden despite higher MPA exposure in patients with severe MMF-related gastrointestinal side-effects. Fundam Clin Pharmacol 2009; 23: 617-624
17. Baraldo M, Isola M, Feruglio MT et al. Therapeutic mycophenolic acid monitoring by means of limited sampling strategy in orthotopic heart transplant patients. Transplant Proc 2005; 37: 2240-2243 (Pubitemid 40956420)
18. Budde K. Review of the immunosuppressant enteric-coated mycophenolate sodium. Expert Opin Pharmacother 2004; 5: 1333-1345 (Pubitemid 38885793)
19. Vogl M, Weigel G, Seebacher G et al. Evaluation of the Emit mycophenolic acid assay from Dade Behring. Ther Drug Monit 1999; 21: 638-643
20. de Winter BC, van Gelder T, Mathot RA et al. Limited sampling strategies drawn within 3 hours postdose poorly predict mycophenolic acid area-under-the-curve after enteric-coated mycophenolate sodium. Ther Drug Monit 2009; 31: 585-591
21. Djabarouti S, Duffau P, Estibaliz L et al. Therapeutic drug monitoring of mycophenolate mofetil and enteric-coated mycophenolate sodium in patients with systemic lupus erythematosus. Expert Opin Pharmacother 2010; 11: 689-699
22. Sommerer C, Muller-Krebs S, Schaier M et al. Pharmacokinetic and pharmacodynamic analysis of enteric-coated mycophenolate sodium: limited sampling strategies and clinical outcome in renal transplant patients. Br J Clin Pharmacol 2010; 69: 346-357
23. Chan L, Mulgaonkar S, Walker R et al. Patient-reported gastrointestinal symptom burden and health-related quality of life following conversion from mycophenolate mofetil to enteric-coated mycophenolate sodium. Transplantation 2006; 81: 1290-1297 (Pubitemid 43804549)
24. Cattaneo D, Merlini S, Zenoni S et al. Influence of co-medication with sirolimus or cyclosporine on mycophenolic acid pharmacokinetics in kidney transplantation. Am J Transplant 2005; 5: 2937-2844
25. Mohammadpour AH, Nazemian F, Abtahi B et al. Estimation of abbreviated mycophenolic acid area under the concentration-time curve during early posttransplant period by limited sampling strategy. Transplant Proc 2008; 40: 3668-3672
26. Kuypers DR, Ekberg H, Grinyó J et al. Mycophenolic acid exposure after administration of mycophenolate mofetil in the presence and absence of cyclosporin in renal transplant recipients. Clin Pharmacokinet 2009; 48: 329-341
27. Kuypers DR, Claes K, Evenepoel P et al. Long-term changes in mycophenolic acid exposure in combination with tacrolimus and corticosteroids are dose dependent and not reflected by trough plasma concentration: a prospective study in 100 de novo renal allograft recipients. J Clin Pharmacol 2003; 43: 866-880 (Pubitemid 36886107)
28. Miura M, Satoh S, Niioka T et al. Early phase limited sampling strategy characterizing tacrolimus and mycophenolic acid pharmacokinetics adapted to the maintenance phase of renal transplant patients. Ther Drug Monit 2009; 31: 467-474
29. Brunet M, Oppenheimer F, Martorell J et al. Mycophenolic acid monitoring: evaluation of the EMIT MPA immunoassay in kidney and lung transplantation. Transplant Proc 1999; 31: 2275-2276 (Pubitemid 29433907)
30. Hosotsubo H, Takahara S, Imamura R et al. Analytic validation of the enzyme multiplied immunoassay technique for the determination of mychophenolic acid in plasma from renal transplant recipients compared with a high-performance liquid chromatographic assay. Ther Drug Monit 2001; 23: 669-674 (Pubitemid 33086497)